Expedeon Develops Technology to Increase Sensitivity of Diagnostic Tests
February 19th, 2013
World healthcare models are continuously facing financial challenges when it comes to providing for an ageing population. The current models for provision are increasingly questioned with the upward trend in healthcare spending becoming a significant portion of the GDP. One solution to alleviate the ever increasing burden is earlier detection of disease using more accurate and sensitive diagnostic kits.
Expedeon has recently launched a technology called Thunder-Link® which will facilitate the development of diagnostic tests. The innovative technology has been designed to allow non-specialists to engineer oligonucleotide conjugates with ease. Such biomolecule complexes are increasingly used in high-sensitivity diagnostic kits, and are designed to overcome limited sensitivity and linear range often encountered with traditional antibody-enzyme conjugates. Prior to Thunder-Link® such biomolecules were difficult and expensive to develop and required specialist knowledge.
Commenting on the launch Nick Gee, CEO, ‘All of Innova’s products in one way or other are geared towards generating conjugates more easily and quickly and improving assay performance. The launch of the Thunder-Link® range of oligo conjugation products firmly places Innova as a key reagent supplier to the diagnostic industry and will assist in bringing high performance diagnostic kits to market.’
About Expedeon Limited
Expedeon is a growing, dynamic business based in Cambridge, UK. At the core of Innova’s business are Lightning-Link® and InnovaCoat® technologies that simplify the production of antibody-based reagents. The expanding portfolio of products is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. The company is ISO 9001:2008 certified.